Trastuzumab emtansine (T-DM1) vs trastuzumab (H) in Chinese patients (pts) with residual invasive disease after neoadjuvant chemotherapy for HER2-positive breast cancer (BC) in the phase III KATHERINE study

被引：0
|
作者：
Huang, C. [1 ,2 ]
Yang, Y. [3 ,4 ]
Kwong, A. [5 ]
Chen, S-C. [6 ]
Tseng, L-M. [7 ]
Liu, M-C. [8 ]
Shen, K. [9 ]
Wang, S. [10 ]
Ng, T-Y. [11 ]
Feng, Y. [12 ]
Sun, G. [12 ]
Yan, I. R. [12 ]
Shao, Z. [13 ]
机构：
[1] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan
[2] Natl Taiwan Univ, Coll Med, Taipei, Taiwan
[3] China Med Univ, Taichung Vet Gen Hosp, Taipei, Taiwan
[4] China Med Univ, Sch Med, Taipei, Taiwan
[5] Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Peoples R China
[6] Chang Gung Med Fdn, Div Gen Surg, Taipei, Taiwan
[7] Taipei Vet Gen Hosp, Dept Surg, Taipei, Taiwan
[8] Koo Fdn Sun Yat sen Canc Ctr, Oncol, Taipei, Taiwan
[9] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai, Peoples R China
[10] Sun Yat Sen Univ, Canc Ctr, Med Oncol, Guangdong Sheng, Peoples R China
[11] Tuen Mun Hosp, Clin Oncol, Hong Kong, Peoples R China
[12] Roche China Holding Ltd, PDO, Shanghai, Peoples R China
[13] Fudan Univ, Shanghai Canc Ctr, Breast Surg, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1O
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
    Loibl, Sibylle
    Huang, Chiun-Sheng
    Mano, Max S.
    Mamounas, Eleftherios P.
    Geyer, Charles E.
    Untch, Michael
    Thery, Jean-Christophe
    Schwaner, Ingo
    Limentani, Steven
    Loman, Niklas
    Lubbe, Kristina
    Chang, Jenny C.
    Hatschek, Thomas
    Tesarowski, David
    Song, Chunyan
    de Haas, Sanne Lysbet
    Boulet, Thomas
    Lambertini, Chiara
    Wolmark, Norman
    NPJ BREAST CANCER, 2022, 8 (01)
  • [22] Metastatic HER2-positive Breast Cancer New Perspectives with Trastuzumab Emtansine (T-DM1)
    Satzger, Ulla
    ONKOLOGIE, 2013, 36 (09): : 525 - 525
  • [23] Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
    Sibylle Loibl
    Chiun-Sheng Huang
    Max S. Mano
    Eleftherios P. Mamounas
    Charles E. Geyer
    Michael Untch
    Jean-Christophe Thery
    Ingo Schwaner
    Steven Limentani
    Niklas Loman
    Kristina Lübbe
    Jenny C. Chang
    Thomas Hatschek
    David Tesarowski
    Chunyan Song
    Sanne Lysbet de Haas
    Thomas Boulet
    Chiara Lambertini
    Norman Wolmark
    npj Breast Cancer, 8
  • [24] TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT)
    Tolaney, Sara M.
    Trippa, Lorenzo
    Barry, William
    Hu, Jiani
    Dang, Chau
    Yardley, Denise
    Isakoff, Steven
    Valero, Vicente
    Faggen, Meredith
    Mulvey, Therese
    Bose, Ron
    Weckstein, Douglas
    Wolff, Antonio
    Reeder-Hayes, Katherine
    Rugo, Hope
    Ramaswamy, Bhuvaneswari
    Zuckerman, Dan
    Hart, Lowell
    Gadi, Vijayakrishna K.
    Constantine, Michael
    Cheng, Kit
    Briccetti, Frederick
    Schneider, Bryan
    Garrett, Merrill
    Marcom, Kelly
    Albain, Kathy
    DeFusco, Patricia
    Tung, Nadine
    Ardman, Blair
    Nanda, Rita
    Jankowitz, Rachel
    Demeo, Michelle
    Partridge, Ann
    Burstein, Harold
    Winer, Eric P.
    Krop, Ian
    CANCER RESEARCH, 2020, 80 (04)
  • [25] Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis
    Loibl, Sibylle
    Mano, Max
    Untch, Michael
    Huang, Chiun-Shen
    Mamounas, Eleftherios
    Wolmark, Norman
    Knott, Adam
    Siddiqui, Asna
    Boulet, Thomas
    Nyawira, Beatrice
    Restuccia, Eleonora
    Geyer, Charles
    CANCER RESEARCH, 2024, 84 (09)
  • [26] Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis
    Untch, Michael
    Loibl, Sibylle
    Mano, Max S.
    Huang, Chiun-Sheng
    Mamounas, Eleftherios P.
    Wolmark, Norman
    Knott, Adam
    Siddiqui, Asna
    Boulet, Thomas
    Nyawira, Beatrice
    Restuccia, Eleonora
    Geyer, Charles E.
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 233 - 234
  • [27] Impact of trastuzumab emtansine (T-DM1) on spleen volume in patients with HER2-positive metastatic breast cancer
    Akyildiz, Arif
    Ismayilov, Rashad
    Abdurrahimli, Najmaddin
    Ormanci, Aylin
    Guven, Deniz Can
    Tuncel, Murat
    Onur, Mehmet Ruhi
    Aksoy, Sercan
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 55 (02) : 100 - 105
  • [28] Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases
    Jacot, William
    Pons, Elvire
    Frenel, Jean-Sebastien
    Guiu, Severine
    Levy, Christelle
    Heudel, Pierre Etienne
    Bachelot, Thomas
    D'Hondt, Veronique
    Darlix, Amelie
    Firmin, Nelly
    Romieu, Gilles
    Thezenas, Simon
    Dalenc, Florence
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 157 (02) : 307 - 318
  • [29] Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases
    William Jacot
    Elvire Pons
    Jean-Sébastien Frenel
    Séverine Guiu
    Christelle Levy
    Pierre Etienne Heudel
    Thomas Bachelot
    Véronique D’Hondt
    Amélie Darlix
    Nelly Firmin
    Gilles Romieu
    Simon Thezenas
    Florence Dalenc
    Breast Cancer Research and Treatment, 2016, 157 : 307 - 318
  • [30] The evolving role of trastuzumab emtansine (T-DM1) in HER2-positive breast cancer with brain metastases
    Dong, Rongrong
    Ji, Jiali
    Liu, Hong
    He, Xuexin
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 143 : 20 - 26
12345